The
CRISPR and Cas gene editing is a technique used to edit genes by altering,
removing, or adding sections of the genomic sequence. It has applications in
curing genetic disorders, developing disease-resistant organisms, and engineering
model organisms for medical research. The technology works by using an
engineered nuclease to cut DNA at a targeted location in the genome. This
ability to make precise edits in the genome has made CRISPR one of the most
widely used genome-editing technologies. The applications of gene editing are
vast ranging from developing disease resistant plants and animals to treating
genetic disorders in humans.
The
Global Crispr And Cas Gene Market is estimated to be valued at US$ 1.78 Bn in
2024 and is expected to exhibit a CAGR of 5.2% over the forecast period 2024 to
2031.
Key Takeaways
Key players operating in the Crispr and Cas gene market are Rescroft Ltd., USSC
Group, Inc., Magna International, Inc., Rojac Urethane Limited, GRAMMER AG,
TransCal, Freedman Seating Co., Delimajaya Group, Franz Kiel GmbH, iFoam Ltd.,
Compin-Fainsa, FlexoFoam Pvt. Ltd., FISA Srl, FENIX Group, LLC, and Kustom
Seating Unlimited, Inc. and Others. CRISPR technology has found widespread
applications in treating genetic disorders and developing new crop variants and
disease-resistant animals. The technology provides cheap, simple and precise
editing compared to other gene-editing tools thus driving its adoption. Various
government funding and initiatives to support stem cell and gene therapy
research is fueling demand. Technological advancements like enhanced accuracy
and expanded editable genetic elements have made CRISPR more effective.
Market trends
Precise gene editing is facilitating development of therapeutic solutions for
various genetic conditions like sickle cell anemia, cystic fibrosis, cancer
etc. Growing R&D efforts from pharmaceutical companies and research
institutes indicate strong potential in disease treatment. Adoption in
agriculture sector is growing for traits improvement in major crops. Precise
modification of plants is helping develop drought/pest resistant and higher
yielding variants. The technology also finds increasing use for environmental
protection by developing phytoremediation plants.
Market Opportunities
One of the key opportunities is advancement of
Crispr
And Cas Gene Market Size technology for human germline editing which
could eliminate genetic diseases in future generations. This presents both
scientific challenges and ethical concerns which needs addressing through
responsible research practices. Adoption in cell and gene therapy offers strong
growth potential. Use of CRISPR systems to edit the microbiome responsible for
several health conditions presents new avenues. Collaboration between
technology providers, researchers and industries would help accelerate
commercialization efforts and tap market opportunities.
Impact of COVID-19 on Crispr and Cas Gene Market Growth
The COVID-19 pandemic has significantly impacted the growth of the Crispr and
Cas gene market. Demand for disease diagnosis, treatment, and vaccines
development using CRISPR-Cas9 gene editing technologies has increased manifold
during this period. With rising COVID-19 infections worldwide, research
activities focusing on utilizing CRISPR for developing rapid point-of-care
diagnostics, antiviral therapeutics, and vaccines against SARS-CoV-2 virus have
accelerated. Various research institutes and biotech companies have initiated
projects to detect and diagnose COVID-19 using CRISPR Cas-based technologies.
Similarly, efforts are ongoing to design CRISPR therapies against coronavirus.
However, supply chain disruptions caused by lockdowns and restrictions imposed
globally resulted in delays and postponements of some ongoing research
activities in 2020. In 2021 and beyond, implementation of strategies enabling
uninterrupted research operations is expected to boost the Crispr and Cas gene
market growth fueled by COVID-19 driven demands.
North America holds the largest share of the Crispr and Cas gene market,
followed by Europe and Asia Pacific. North American market is valued at over
US$ 1 Bn in 2024 due high adoption of gene therapies and editing technologies
in research and clinical settings in the US and Canada. Europe accounts for
around 30% market share driven by increasing funding for genomics and
biotechnology research from countries like the UK, Germany, France and others.
Asia Pacific market is growing at the fastest pace with China at forefront,
expanding at a double digit CAGR between 2024-2031. Collaborations between
Chinese and international companies, strengthening research infrastructure and
government support are major factors contributing to APAC's high growth. The
Middle East & Africa region also offers immense opportunities for Crispr
and Cas gene market players owing to improving healthcare landscape and
investment in life sciences capable of transforming disease management in the
coming decade.
The global Covid-19 pandemic has particularly accelerated growth of the Crispr
and Cas gene market in Asia Pacific region. Due to early outbreak and high
infections, countries across APAC aggressively focused on developing rapid and
affordable diagnostics as well as therapeutic solutions using Crispr
technology. Researchers in South Korea, China and Singapore achieved
breakthroughs in Covid detection using Crispr gene editing. Similarly, projects
to design antiviral Crispr therapies against SARS-CoV-2 virus gained momentum.
Support through initiatives like 'Gene and Cell Engineering Innovation and
Application Key Technology Platform' in China boosted regional market growth
during the crisis. With growing genomics research capabilities, Asia Pacific is
expected to witness strongest recovery in post-Covid scenario and emerge as the
fastest growing regional market for Crispr and Cas gene globally.
Get more insights on – Crispr
And Cas Gene Market
About Author:
Money Singh is a seasoned content writer with over
four years of experience in the market research sector. Her expertise spans
various industries, including food and beverages, biotechnology, chemical and
materials, defense and aerospace, consumer goods, etc. (https://www.linkedin.com/in/money-singh-590844163)
Comments
Post a Comment